GlassScriptPhysician profile
Vikram Mehra
NPI 1801848957
$1,197,914.72
in general payments reported to CMS, 2019-2025
26 companies · $187K in 2025
The $187K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $54K · 2021: $94K · 2022: $175K · 2023: $246K · 2024: $278K · 2025: $187K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $507K · Travel and Lodging: $105K · Consulting Fee: $69K · Food and Beverage: $28K · Honoraria: $2,750 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $506,507.50 |
| Travel and Lodging | $104,876.23 |
| Consulting Fee | $69,363.00 |
| Food and Beverage | $28,008.37 |
| Honoraria | $2,750.00 |
| Education | $124.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $564,493.42 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $145,867.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $140,078.09 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $95,854.47 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $94,197.52 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $41,358.62 | 2019-2022 | |
| Axsome Therapeutics, INC. | $39,563.13 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $34,848.24 | 2022-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $26,753.81 | 2019-2025 | Ingrezza |
| Corium, LLC | $4,385.23 | 2021-2025 | Azstarys |
| Indivior INC. | $2,507.08 | 2019-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,886.97 | 2020-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,620.00 | 2025 | Abilify Asimtufii |
| Abbvie INC. | $1,306.07 | 2021-2025 | |
| Lundbeck LLC | $1,299.00 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $553.63 | 2019-2025 | Invega Sustenna, Invega, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $356.01 | 2019-2025 | Trintellix |
| Eisai INC. | $272.86 | 2020-2022 | |
| Allergan, INC. | $242.87 | 2019-2020 | |
| Almatica Pharma LLC | $118.21 | 2022-2025 | Loreev Xr |
| Bausch Health US, LLC | $106.46 | 2019-2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $104.88 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $81.32 | 2019-2021 | |
| Livanova USA, INC. | $21.48 | 2021 | |
| Luye Pharma (USA) LTD. | $19.70 | 2025 | Erzofri Extended-Release |
| Vertical Pharmaceuticals, LLC | $18.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.